| Pair Name | Atractylenolide I, Erlotinib | ||
| Phytochemical Name | Atractylenolide I (PubChem CID: 5321018 ) | ||
| Anticancer drug Name | Erlotinib (PubChem CID: 176870 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Atractylenolide I, Erlotinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | CYB5R2 | hsa51700 |
| Down-regulation | Expression | EZH2 | hsa2146 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
| In Vivo Model | A549 cells, carrying the luciferase reporter gene (1×10⁷ cells), were subcutaneously injectinto the mice. | |||
| Result | Targeting the PDK1- and HOTAIR-mediated downstream molecule EZH2 by the combination of ATL-1 and erlotinib potentially facilitates the development of an additional novel strategy to combat lung cancer | |||
| No. | Title | Href |
|---|---|---|
| 1 | Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells. Cell Physiol Biochem. 2018;49(4):1615-1632. doi: 10.1159/000493497. | Click |
